Bifogade filer
Isofol_Annual Report 2025
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
GOTHENBURG, Sweden, April 10, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2025 are now available, in Swedish as well as an English translation, on the company's website, www.isofolmedical.com.
The information in the press release is intended for investors.
CEO’s comment
“Isofol made clear progress in 2025, focusing on resuming the clinical development of arfolitixorin. After the end of the fiscal year, we reported positive preliminary interim results from the ongoing study. Furthermore, we have had a productive dialogue with regulatory authorities, deepened our collaboration with partner Solasia Pharma K.K., and strengthened our financial position,” says CEO Petter Segelman Lindqvist.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0) 738 73 34 18
This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on April 10, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.